Cognition Therapeutics, Inc.

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics targeting age-related degenerative diseases and disorders specific to the central nervous system, or CNS, and retina with a goal to develop treatments that can modify the diseases in patients with these disorders. The company has expert experience in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses. It also acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.